For Alkermes' Vivitrol, FDA Not Viewing Trial Results From Russia With Love
This article was originally published in The Pink Sheet Daily
Underreporting of adverse events may be a Russian "cultural norm," the agency says in a briefing document released in advance of an advisory panel review of Alkermes' Vivitrol (naltrexone) for opioid dependence.
You may also be interested in...
Alkermes' four-year-old Vivitrol has been struggling to get its head above water as a therapy for alcoholism. But fast-track status for a new opioid addiction indication and a slew of supportive studies at the American Psychiatric Association meeting offer the $900-a-month injectable a shot at recovery
Biotech cites need to educate physicians about long-acting injectable for alcohol dependence.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.